Oscient Pharmaceuticals News

MISSISSAUGA, Ontario, March 7, 2012 -- AllPennyStocks.com Media, Inc. announces its latest article titled "Junior Drug Maker Shares Rise on Acquisition Rights to Bronchitis/Pneumonia Drug." Companies mentioned in this article include Pfizer , Abbott , Cornerstone Therapeutics and Merus Labs International Inc.

The Malvern, Pa., biopharmaceutical company said Monday Andrew I. Koven is its new executive vice president, chief administrative officer and general counsel, and Mark A. Glickman is the new senior vice president, sales.

Just Released: Oscient Pharmaceuticals Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile 2011-05-14 07:02:25 - New Pharmaceuticals market report from GlobalData: "Oscient Pharmaceuticals Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Oscient Pharmaceuticals Corporation - Pharmaceuticals & Healthcare ...

Its product line consists of ANTARA, FACTIVE and Ramoplanin. ANTARA and FACTIVE are FDA approved products marketed in the US.

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.